Mark Fisher
Directeur/Membre du Conseil chez Exomedica Ltd.
Profil
Mark Fisher is currently the Director at Exomedica Ltd.
He previously held positions as Chairman & Chief Executive Officer at Oncomorph Analysis Ltd., Chief Executive Officer & Director at Attomarker Ltd., Principal at NHS Innovations South East Ltd., and Principal at MedTech Innovation Center.
Dr. Fisher has a graduate and doctorate degree from University College London and an undergraduate degree from London South Bank University.
Postes actifs de Mark Fisher
| Sociétés | Poste | Début |
|---|---|---|
Exomedica Ltd.
 Exomedica Ltd. Financial ConglomeratesFinance Exomedica Ltd. develops and funds medical technology innovation. The firm focus on technology deriving from academic and clinical research. It current portfolio includes innovations in laparoscopy, fertility, gynecology, cancer diagnostics and diabetes. The company was founded on 16 February, 2004 and is headquartered in London, the United Kingdom. | Directeur/Membre du Conseil | 01/08/2005 |
Anciens postes connus de Mark Fisher
| Sociétés | Poste | Fin |
|---|---|---|
Oncomorph Analysis Ltd.
 Oncomorph Analysis Ltd. Packaged SoftwareTechnology Services Oncomorph Analysis Ltd is a UK-based software company founded in 2007. The company's mission is to develop innovative technology to automate the analysis of medical images. They are creating software that is designed to model tissues in 3 dimensions and to classify tissue types using information on texture and the histology of disease. By automatically extracting and refining the information yielded by a medical image at point-of-care, Oncomorph Analysis hopes to benefit patients in a number of ways includes eliminating inter-observer variability in the interpretation of medical imaging data, informing the frequency and accuracy of tissue biopsy, automating the normally challenging diagnosis of early stage (non-palpable) disease and combining the diagnostic and surgical planning function of imaging technologies. Applications for the Oncomorph Analysis technology are broad however their aims are focused on the need to standardize the interpretation of medical images at a high throughput. They are currently developing its technology for Magnetic Resonance Imaging (MRI) data, to assist in cancer diagnosis and staging. | Directeur Général | 17/09/2013 |
Attomarker Ltd.
 Attomarker Ltd. Electronic Equipment/InstrumentsElectronic Technology Attomarker Ltd. develops medical diagnostic kits. The firm products include array reader technology, allergy, and appex recovery app. Its services include antibody screening, chemical intermediates, and customs synthesis. The company was founded by Andrew Mark Shaw on April 1, 2008 and is headquartered in Exeter, the United Kingdom. | Directeur Général | - |
| NHS Innovations South East Ltd. | Corporate Officer/Principal | - |
| MedTech Innovation Center | Corporate Officer/Principal | - |
Formation de Mark Fisher
| University College London | Doctorate Degree |
| London South Bank University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Oncomorph Analysis Ltd.
Oncomorph Analysis Ltd. Packaged SoftwareTechnology Services Oncomorph Analysis Ltd is a UK-based software company founded in 2007. The company's mission is to develop innovative technology to automate the analysis of medical images. They are creating software that is designed to model tissues in 3 dimensions and to classify tissue types using information on texture and the histology of disease. By automatically extracting and refining the information yielded by a medical image at point-of-care, Oncomorph Analysis hopes to benefit patients in a number of ways includes eliminating inter-observer variability in the interpretation of medical imaging data, informing the frequency and accuracy of tissue biopsy, automating the normally challenging diagnosis of early stage (non-palpable) disease and combining the diagnostic and surgical planning function of imaging technologies. Applications for the Oncomorph Analysis technology are broad however their aims are focused on the need to standardize the interpretation of medical images at a high throughput. They are currently developing its technology for Magnetic Resonance Imaging (MRI) data, to assist in cancer diagnosis and staging. | Technology Services |
Exomedica Ltd.
Exomedica Ltd. Financial ConglomeratesFinance Exomedica Ltd. develops and funds medical technology innovation. The firm focus on technology deriving from academic and clinical research. It current portfolio includes innovations in laparoscopy, fertility, gynecology, cancer diagnostics and diabetes. The company was founded on 16 February, 2004 and is headquartered in London, the United Kingdom. | Finance |
| MedTech Innovation Center | |
| NHS Innovations South East Ltd. | |
Attomarker Ltd.
Attomarker Ltd. Electronic Equipment/InstrumentsElectronic Technology Attomarker Ltd. develops medical diagnostic kits. The firm products include array reader technology, allergy, and appex recovery app. Its services include antibody screening, chemical intermediates, and customs synthesis. The company was founded by Andrew Mark Shaw on April 1, 2008 and is headquartered in Exeter, the United Kingdom. | Electronic Technology |
